* CEO highlighted potential future M&A * Finding the balance between efficiency and individuality * ...
Fastators omsättning minskar, samtidigt som förlusten har halverats under perioden.
Last evening, Guard Therapeutics announced its evaluation of the complete results from the phase IIb...
Redeye comments on the survival readout in the phase IIb study TRIFOUR, which investigates nadunolim...
Redeye provides a comment on the webcast of 4 December, which provided more details on the negative ...
* Riding the infrastructure spending wave * Internal efficiency improvements to continue * 8-6x EBIT...
Redeye finds the subscription rate somewhat lacklustre, although since the issue was fully guarantee...
* SATCOM demand is strong * There is good, untapped potential with Ovzon-3 * The stock trades at 13x...
Redeye returns with an update on Sprint Bioscience following recent events and the Q3 report.
Incap acquires Lacon which has production sites in Germany and in Romania.
Redeye updates valuation and estimates to reflect the upcoming spin-off of Coffee Stain, which is du...
Redeye comments on the negative phase II readout and changes its base case.
* Strong potential for margin improvements * Short term priorities presented * Favourable sales mix ...
Redeye leaves a comment following OncoZenge’s announcement of an amended agreement with Molteni Farm...
* Strong early data point with 25% conversion rate for Doro in D2C * .
* CFO and new CEO gave a general presentation * Some positive market signs, mainly in public and tel...
Siili lowered its guidance for EBITA; the new guidance range mid-point stands c.
Redeye comments on decision by the VGR Regional Board regarding Millennium and the modular alternati...
ChargePanels månatliga omsättning har ökat med 18,3 respektive 34,4 procent under september och okto...
Redeye provides a summary of Sdiptech’s CMD. The event presented slightly updated financial targets,...
